Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Somatostatin Receptor Positive · Gastrointestinal Neuroendocrine Tumors · Pheochromocytoma · Paragangliomas
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (National Cancer Institute Referral Office) · ncimo_referrals@mail.nih.gov · (888) 624-1937
Study leads
Frank I Lin, M.D.
Principal Investigator
National Cancer Institute (NCI)